Compare JFIN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | EQ |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.7M | 129.0M |
| IPO Year | 2018 | 2018 |
| Metric | JFIN | EQ |
|---|---|---|
| Price | $2.86 | $2.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 97.5K | ★ 845.0K |
| Earning Date | 06-03-2026 | 05-25-2026 |
| Dividend Yield | ★ 17.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.70 | $0.29 |
| 52 Week High | $18.70 | $3.54 |
| Indicator | JFIN | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 30.03 | 52.86 |
| Support Level | $2.70 | $1.68 |
| Resistance Level | $4.45 | $3.15 |
| Average True Range (ATR) | 0.29 | 0.26 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 9.97 | 26.41 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.